Skip to main content
. 2020 Jun 19;12:4725–4734. doi: 10.2147/CMAR.S254972

Table 3.

Clinico-Pathological Detail and Follow-Up of All L-PSDs

Case Sex/Age Symptom Size (cm) Location to Ampulla Mitotic Count Risk Adjuvant Imatinib OS
Opposite Sup./Inf.
1 F/63 GI Bleeding 1.6 Yes Superior 5/50HPF Very low No 53.1 months
2 M/59 GI Bleeding 3.0 Yes Inferior 8/50HPF High Yes 50.8 months
3 F/71 Pain 2.0 Yes Superior 2/50HPF Very Low No 44.6 months
4 M/46 Pain 3.3 Yes Superior 1/50HPF Low No 30.3 months
5 F/50 Pain 4.0 Yes Inferior 1/50HPF Low No 24.2 months
6 M/66 Asymptomatic 4.0 Yes Inferior 1/50HPF Low No 25.3 months
7 F/65 GI Bleeding 2.5 Yes Superior 2/50HPF Low No 14.9 months
8 F/44 Pain 4.6 Yes Inferior 4/50HPF Low No 14.5 months
9 M/61 GI Bleeding 3 Yes Inferior 4/50HPF Low No 14.0 months